KCT0008320尚未招募Unknown
An exploratory study on the safety and efficacy of upper extremity motor function recovery after neuromodulatory stimulation of the contralateral primary motor cortex (M1 cortex) using low-intensity focused ultrasound (NS-US200) in patients with subacute ischemic stroke
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19(Year) 至 85(Year)（—）
- 性别
- All
入选标准
- •1) Adult men and women aged 19 or older but less than 85
- •2) Patients diagnosed with supratentorial stroke through brain MRI due to their first ischemic stroke, which can affect upper limb function by invading the cortical or subcortical area of the brain, regardless of the occurrence mechanism of ischemic strokes, such as thrombotic, embolic, or lacunar stroke, According to the Korean Clinical Practice Guidelines for Stroke Rehabilitation, repetitive transcranial magnetic stimulation (rTMS) is recommended to improve upper-limb function after stroke rehabilitation. But it isn't clear who should use rTMS or how well it works for stroke rehabilitation based on where the lesion is or what caused the stroke. Caution should be used because there are some risks and side effects. Low-intensity focused ultrasound stimulation is considered valid for stroke patients with lesions affecting upper limb function. This is because it is hard to find a single cause for a stroke, and previous studies and guidelines have focused on the functional impairment of upper-limb function rather than the location of the lesion.
- •3) Patients in the subacute phase, within three months of an ischemic stroke, based on the screening time, which is when the maximum neural plasticity of the brain occurs after a stroke.
- •4) Patients with persistent hemiparetic motor impairment due to ischemic stroke at the time of screening: specifically, patients who are evaluated to have muscle weakness at the trunk or proximal part of the affected upper limb with a grade of 4 (good grade) or less according to the manual muscle test performed by a physical therapist are targeted.
- •º 0 grade: no muscle contraction
- •º 1 grade: visible or palpable muscle contraction, but the joint movement is impossible
- •º 2 grade: active joint movement in a gravity-free state
- •º 3 grade: active joint movement against gravity
- •º 4 grade: active joint movement against gravity and some resistance
- •º 5 grade: active normal joint movement against gravity and full resistance
- •5) Patients who have clear consciousness, are able to cooperate with the study, and have voluntarily agreed to participate in this clinical trial.
排除标准
- •1.Patients with grade 5 upper limb muscle strength without significant upper limb muscle weakness after a stroke.
- •2.Pregnant or breastfeeding women (if a woman of childbearing potential has a positive urine HCG test).
- •3.Patients with abnormalities of the cerebral hemisphere or a history of cerebral disorders, including cerebrospinal fluid stenosis, brain tumors, abscesses, hydrocephalus, trauma, skull fractures, or congenital brain malformations, observed on brain imaging tests (CT or MRI), other than ischemic stroke.
- •4.Patients who have undergone baseline blood tests, including the following ranges: ? Kidney disease (creatinine> 2.0 mg/dL) ? Thrombocytopenia (less than 100 x 103/µL) ? Leukopenia (less than 4.0 x 103/µL) ? Liver disease (AST, ALT, total bilirubin values are more than twice the upper limit of the normal range)
- •5.Uncontrollable cardiac disease patients (unstable congestive heart failure, myocardial infarction, ventricular tachycardia, or third-degree atrioventricular block)
- •6.Patients with a history of contact dermatitis or sensitive skin abnormalities.
- •7.Patients with implanted electronic medical devices such as pacemakers that prevent magnetic resonance imaging (MRI) scanning.
- •8.Patients with a history of epilepsy, Parkinson's disease, agoraphobia, or other psychiatric disorders.
- •9.Patients who have a history of taking or are currently taking drugs that affect the peripheral or central nervous system for purposes other than improving cognitive function after a stroke.
- •10.Patients with the unstable general condition due to current infectious diseases such as fever.
- •11.Patients who require stable hemostasis after various surgeries, etc. In addition, in cases where participation in this clinical trial is deemed inappropriate at the discretion of the investigator.
研究者
相似试验
招募中
2 期
An exploratory study of the safety and efficacy of disulfiram in progressive fibrosing interstitial lung diseaseinterstitial lung diseaseprogressive fibrosing interstitial lung diseaseD017563JPRN-jRCTs031220648rushiyama Hirokazu10
招募中
不适用
An exploratory study on the efficacy and safety of Hangesyasinto (TJ-14) for DCF chemotherapy or DCF-RT chemoradiotherapy induced diarrhea in the patients with advanced esophageal cancer.esophageal cancerJPRN-UMIN000023825Dokkyo Medical University24
招募中
不适用
A exploratory study of the efficacy and safety of oxaliplatin in combination with S-1 in the treatment of non-resectable gastric cancernon-resectable gastric cancer or reccurent gastric cancerJPRN-UMIN000002463niversity of Tokyo Hospital20
已完成
不适用
An exploratory study of the efficacy and safety of yokukansan for postoperative delirium in patients who underwent surgical resection of malignant tumor of digestive system.Digestive system cancerJPRN-UMIN000013235Hitachi,Ltd.,Hitachi General Hospital40
进行中（未招募）
不适用
An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe DiseasePompe disease (acid alpha-glucosidase deficiency)MedDRA version: 17.1Level: LLTClassification code 10036143Term: Pompe's diseaseSystem Organ Class: 100000004850EUCTR2015-000584-14-Outside-EU/EEAGenzyme Corporation Inc4